ArticleFuture oncology (London, England)2022

HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.

Josep Tabernero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.